Full Text Journal Articles by
Author Christian Pfister

Advertisement

Find full text journal articles






Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma.

Hugo Georges Arthur Dupuis, Ala Chebbi, Louis Surlemont, Olivier Rigal, Frédéric Di Fiore, Christian Pfister, François-Xavier Nouhaud,

<h4>Background</h4>immunotherapy became the first line treatment of metastatic renal cell carcinoma (mRCC). Nevertheless, a better understanding of the specificities of targeted therapies (TT) in the elderly population could be helpful in order to improve the management of mRCC in this population. The aim of this retrospective study was to assess ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2021, 10(6):2418-2426]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.

Klaus Kucher, Donald Johns, Frank Wagner, Khalid Abd-Elaziz, Caroline Derne, Oleksandr Sverdlov, Christian U Pfister, Berthold Langguth,

To evaluate efficacy and safety of BGG492 (selurampanel; an orally active, competitive AMPA glutamate receptor antagonist) in patients with moderate-to-catastrophic chronic subjective tinnitus. Study (NCT01302873) enrolled patients with subjective tinnitus based on THI severity grade 3, 4 or 5 (moderate, severe or catastrophic), and those with chronic (>6 and <36 ... Read more >>

Prog Brain Res (Progress in brain research)
[2021, 260:423-440]

Cited: 0 times

View full text PDF listing >>



Advertisement

Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.

François-Xavier Nouhaud, Marouene Chakroun, Claire Lenormand, Idir Ouzaid, Benoit Peyronnet, Alexandre Gryn, Thomas Prudhomme, Vivien Grafeille, Michel Soulié, Mathieu Roumiguié, Grégory Verhoest, Evanguelos Xylinas, Abderrazak Bouzouita, Mohamed Chebil, Christian Pfister,

<h4>Purpose</h4>To assess whether progressive and primary muscle invasive bladder cancer (MIBC) have different prognosis after radical cystectomy or not. To date only a few data are available on this topic with conflicting results. Further studies on large cohort are needed to clarify these outcomes that may influence bladder cancer management ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(3):195.e1-195.e6]

Cited: 1 time

View full text PDF listing >>



Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review.

Thomas Seisen, Andrea Mari, Riccardo Campi, Benoit Peyronnet, Karim Bensalah, Nathalie Rioux-Leclercq, Christian Pfister, Françoise Gobet, Alexandre De La Taille, Yves Allory, Evanguelos Xylinas, Yann Neuzillet, Camelia Radulescu, Jean-Luc Descotes, Géraldine Saada-Sebag, Jacques Irani, Céline Delpech-Debiais, Pierre Bigot, Caroline Eymerit, Sebastien Crouzet, Florence Mege-Lechevallier, Alain Ruffion, Myriam Decaussin-Petrucci, Stéphane Droupy, Pascal Roger, Xavier Durand, Philippe Camparo, Olivier Cussenot, Eva Compérat, Morgan Rouprêt,

<h4>Background</h4>The current pathological tumour-node-metastasis (pTNM) classification for upper tract urothelial carcinoma (UTUC) does not include any risk stratification of pT3 renal pelvicalyceal tumours.<h4>Objective</h4>To assess the prognostic impact of pT3 subclassification in a multicentre cohort of patients with UTUC of the renal pelvicalyceal system undergoing radical nephroureterectomy (RNU).<h4>Design, setting, and participants</h4>Data ... Read more >>

Eur Urol Focus (European urology focus)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew R Smith, ,

<h4>Background</h4>Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(11):1040-1049]

Cited: 21 times

View full text PDF listing >>



Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.

Christian Pfister, Gwenaelle Gravis, Aude Fléchon, Michel Soulié, Laurent Guy, Brigitte Laguerre, Nicolas Mottet, Florence Joly, Yves Allory, Valentin Harter, Stéphane Culine, ,

<h4>Background</h4>Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC). Retrospective studies or prospective phase II trials have been reported to use dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). As dd-MVAC has shown higher response rates in ... Read more >>

Eur Urol (European urology)
[2021, 79(2):214-221]

Cited: 8 times

View full text PDF listing >>



Observation vs. early drainage for grade IV blunt renal trauma: a multicenter study.

Ala Chebbi, Benoit Peyronnet, Anthony Giwerc, Lucas Freton, Marine Hutin, Jonathan Olivier, Quentin Langouet, Marina Ruggiero, Ines Dominique, Clémentine Millet, Sébastien Bergerat, Paul Panayatopoulos, Reem Betari, Xavier Matillon, Thomas Caes, Pierre-Marie Patard, Nicolas Szabla, Nicolas Brichart, Axelle Boehm, Laura Sabourin, Kerem Guleryuz, Charles Dariane, Cédric Lebacle, Jérome Rizk, Alexandre Gryn, François-Xavier Madec, Xavier Rod, Gaelle Fiard, Benjamin Pradere, Christian Pfister, François-Xavier Nouhaud, ,

<h4>Introduction</h4>The aim of this study was to compare observation and early drainage by ureteral stenting in patients with blunt renal trauma and urinary extravasation.<h4>Materials and methods</h4>A retrospective national multicenter study was performed including all patients admitted for renal trauma at 17 hospitals between 2005 and 2015. Patients presenting with a ... Read more >>

World J Urol (World journal of urology)
[2021, 39(3):963-969]

Cited: 0 times

View full text PDF listing >>



Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".

Marc-Oliver Grimm, Antoine G van der Heijden, Marc Colombel, Tim Muilwijk, Luis Martínez-Piñeiro, Marko M Babjuk, Levent N Türkeri, Joan Palou, Anup Patel, Anders S Bjartell, Christien Caris, Raymond G Schipper, Wim P J Witjes, ,

<h4>Background</h4>Intravesical instillation of bacillus Calmette-Guérin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity.<h4>Objective</h4>NIMBUS assessed whether a reduced number of standard-dose BCG instillations are noninferior to the standard number and dose in patients with high-grade NMIBC.<h4>Design, setting, and participants</h4>A total of ... Read more >>

Eur Urol (European urology)
[2020, 78(5):690-698]

Cited: 7 times

View full text PDF listing >>



Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management.

Mohamed Ali Essid, Marouene Chakroun, François Xavier Nouhaud, Michael Lair, Françoise Gobet, Christian Pfister,

<h4>Background</h4>Magnetic resonance imaging (MRI) is today strongly recommended in prostate cancer (PCa) diagnosis. Therefore, MRI/ultrasound (MRI/US) fusion-guided biopsy is becoming the new standard patients management.<h4>Methods</h4>We report our experience during the last 4 years using this technique, with a protocol of 6 random cores (instead of the most used 12 cores ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2020, 9(2):629-636]

Cited: 0 times

View full text PDF listing >>



Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.

Christian Pfister, Valentin Harter, Yves Allory, François Radvanyi, Stéphane Culine, ,

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery. A total of 500 patients have been randomized in 28 reference ... Read more >>

Contemp Clin Trials Commun (Contemporary clinical trials communications)
[2020, 17:100536]

Cited: 1 time

View full text PDF listing >>



Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).

Clara Delcourt, Pierre Gemival, François Xavier Nouhaud, Françoise Gobet, Andre Gillibert, Sophie Ferlicot, Jean Christophe Sabourin, Jacques Irani, Christian Pfister,

<h4>Objective</h4>To assess PD-L1 expression in tumor (TC) and tumor infiltrating immune cells (IC) as a predictive factor of BCG therapy failure in high-risk NMIBC.<h4>Materials and methods</h4>Patients treated with complete resection followed by bladder BCG instillation for high-risk NMIBC were included. Early recurrence (ER) was defined as tumor recurrence after BCG ... Read more >>

World J Urol (World journal of urology)
[2020, 38(6):1517-1524]

Cited: 4 times

View full text PDF listing >>



Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.

Eric Voog, Boris Campillo-Gimenez, Claude Elkouri, Franck Priou, Frederic Rolland, Brigitte Laguerre, Chaza Elhannani, Jacques Merrer, Christian Pfister, Emmanuel Sevin, Tifenn L'Haridon, Ali Hasbini, Laura Moise, Annick Le Rol, Jean Pierre Malhaire, Remy Delva, Elodie Vauléon, Oana Cojocarasu, Philippe Deguiral, Isabelle Cumin, Caroline Cheneau, Friedrike Schlürmann, Valérie Delecroix, Elouen Boughalem, Delphine Mollon, Catherine Ligeza-Poisson, Sophie Abadie-Lacourtoisie, Erik Monpetit, Thierry Chatellier, Henry Desclos, Elodie Coquan, Florence Joly, Jean Yves Tessereau, Sandra Dupuy, Delphine Déniel Lagadec, Fanny Marhuenda, Francoise Grudé,

The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of the context of a clinical trial, the treatments are used sequentially. We describe results under real-life conditions of a sequential ... Read more >>

Int J Cancer (International journal of cancer)
[2020, 146(6):1643-1651]

Cited: 1 time

View full text PDF listing >>



Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R Smith, ,

<h4>Background</h4>Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.<h4>Methods</h4>We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer ... Read more >>

N Engl J Med (The New England journal of medicine)
[2019, 380(13):1235-1246]

Cited: 131 times

View full text PDF listing >>



The maximum detrusor pressure as a predictive factor of success after sphincterotomy in detrusor-sphincter dyssynergia.

Alexandre Hourié, Francois-Xavier Nouhaud, Maximilien Baron, John-David Rebibo, Christian Pfister, Philippe Grise, Jean-Nicolas Cornu,

<h4>Aims</h4>To evaluate the impact of the pre-operative maximum detrusor pressure (MDP) on efficacy outcomes after incontinentation by sphincterotomy or urethral stent placement in male patients with neurogenic detrusor-sphincter dyssynergia (DSD).<h4>Methods</h4>A retrospective study was performed in 41 male patients treated between 2006 and 2013 in a tertiary reference center. All patients ... Read more >>

Neurourol Urodyn (Neurourology and urodynamics)
[2018, 37(8):2758-2762]

Cited: 0 times

View full text PDF listing >>



Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.

Stéphane Culine, Yves Allory, Christian Pfister,

Transl Androl Urol (Translational andrology and urology)
[2018, 7(4):757-759]

Cited: 1 time

View full text PDF listing >>



First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury.

Klaus Kucher, Donald Johns, Doris Maier, Rainer Abel, Andreas Badke, Hagen Baron, Roland Thietje, Steven Casha, Renate Meindl, Baltazar Gomez-Mancilla, Christian Pfister, Rüdiger Rupp, Norbert Weidner, Anis Mir, Martin E Schwab, Armin Curt,

<h4>Background</h4>Neutralization of central nervous system neurite growth inhibitory factors, for example, Nogo-A, is a promising approach to improving recovery following spinal cord injury (SCI). In animal SCI models, intrathecal delivery of anti-Nogo-A antibodies promoted regenerative neurite growth and functional recovery.<h4>Objective</h4>This first-in-man study assessed the feasibility, safety, tolerability, pharmacokinetics, and preliminary ... Read more >>

Neurorehabil Neural Repair (Neurorehabilitation and neural repair)
[2018, 32(6-7):578-589]

Cited: 30 times

View full text PDF listing >>



Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma.

François-Xavier Nouhaud, France Blanchard, Richard Sesboue, Jean-Michel Flaman, Jean-Christophe Sabourin, Christian Pfister, Frédéric Di Fiore,

<h4>Background</h4>Gene copy number variations (CNVs) have been reported to be frequent in renal cell carcinoma (RCC), with potential prognostic value for some. However, their clinical utility, especially to guide treatment of metastatic disease remains to be established. Our objectives were to assess CNVs on a panel of selected genes and ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2018, 16(4):e795-e805]

Cited: 6 times

View full text PDF listing >>



Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, Hakim Mahammedi, Lionel Vedrine, Florence Joly, Loic Mourey, Christian Pfister, Alejandro Goberna, Barbara Lortal, Carine Bellera, Philippe Pourquier, Nadine Houédé,

BACKGROUND:Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation of the PI3K/AKT/mTOR pathway was observed in ... Read more >>

BMC Cancer (BMC cancer)
[2018, 18(1):194]

Cited: 4 times

View full text PDF listing >>



Ladies first: Female and male adult height in Switzerland, 1770-1930.

Nikola Koepke, Joël Floris, Christian Pfister, Frank J Rühli, Kaspar Staub,

When investigating the well-being of a society, the living conditions of females are of special importance, not only due to the immediate impact for those directly involved, but also because of the potential intergenerational effects. Studying the dimorphism in the mean height helps to depict variation in the basic biological ... Read more >>

Econ Hum Biol (Economics and human biology)
[2018, 29:76-87]

Cited: 0 times

View full text PDF listing >>



Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura, Angela Lopez-Gitlitz, Géralyn C Trudel, Byron M Espina, Youyi Shu, Youn C Park, Wayne R Rackoff, Margaret K Yu, Eric J Small, ,

BACKGROUND:Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. METHODS:We conducted a double-blind, placebo-controlled, phase 3 trial involving men ... Read more >>

N Engl J Med (The New England journal of medicine)
[2018, 378(15):1408-1418]

Cited: 249 times

View full text PDF listing >>



Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R. S. Lance, P. S. Nelson, I. M. Thompson, Jr., A. A. Wagner, J. T. Wei and D. W. Lin J Urol 2017;197:1026-1033.

Justine Denize, François-Xavier Nouhaud, Jean-Nicolas Cornu, Christian Pfister,

J Urol (The Journal of urology)
[2017, 198(3):709-711]

Cited: 1 time

View full text PDF listing >>



Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie Vauleon, Pierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges,

<h4>Background</h4>Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.<h4>Methods</h4>We performed a retrospective data ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2017, 80:55-62]

Cited: 2 times

View full text PDF listing >>



Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: A prospective study.

Guillaume Defortescu, Jean-Nicolas Cornu, Sofiane Béjar, Anthony Giwerc, Françoise Gobet, Claire Werquin, Christian Pfister, François-Xavier Nouhaud,

<h4>Objectives</h4>To compare the diagnostic performance of computed tomography, magnetic resonance imaging and contrast enhanced ultrasonography for the assessment of complex renal cysts.<h4>Methods</h4>We carried out a prospective single-center study from January 2012 to December 2013. We included patients with Bosniak category 2F or 3 renal cysts found on computed tomography and ... Read more >>

Int J Urol (International journal of urology : official journal of the Japanese Urological Association)
[2017, 24(3):184-189]

Cited: 12 times

View full text PDF listing >>



Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer.

François X Nouhaud, Jérome Rigaud, Fabien Saint, Marc Colombel, Jacques Irani, Michel Soulie, Christian Pfister,

The objective of this study was to assess at 3 years bacillus Calmette-Guerin (BCG) maintenance treatment for NMIBC using one-third dose schedule and fewer instillations every 3 or 6 months. This was a phase III randomized study including patients with intermediate-risk or high-risk NMIBC, who received, after a full-dose induction ... Read more >>

Anticancer Drugs (Anti-cancer drugs)
[2017, 28(3):335-340]

Cited: 2 times

View full text PDF listing >>



[Urothelial tumors in 2016: Are we at the dawn of a new diagnostic and therapeutic era?]

Christian Pfister,

Ann Pathol (Annales de pathologie)
[2016, 36(6):369-370]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.588 s